Cite
HARVARD Citation
Savage, L. et al. (2019). Regression of Peripheral Subclinical Enthesopathy in Therapy‐Naive Patients Treated With Ustekinumab for Moderate‐to‐Severe Chronic Plaque Psoriasis: A Fifty‐Two–Week, Prospective, Open‐Label Feasibility Study. Arthritis & rheumatology. 71 (4), pp. 626-631. [Online].